Journals / Gülhane Tıp Dergisi / 2021 / Cilt: 63 - Sayı: 3

Factors predicting recurrence in non-muscle invasive bladder cancers

Pages
175–180
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thepresence of carcinoma in situ (CIS) [Hazard ratio (HR): 3.00, 95% CI: 1.2-7.6, p=0.03], femalegender (HR: 2.38, 95% CI: 1.03-5.4, p=0.03) and age >70 years (HR: 1.87, 95% CI: 1.02-3.41,p=0.03) were significantly associated with recurrence.Conclusions: The present study showed that the presence of CIS, female gender, and age >70years were independently associated with the recurrence of NMIBC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: We aimed to assess patients with non-muscle invasive bladder cancer (NMIBC) to findout the factors affecting recurrence after initial treatment.Methods: In this retrospective cohort study, we investigated patients who underwenttransurethral bladder tumor resection (TURB) between January 2014 and April 2020.
📊
Key Findings & Data:Recurrence was considered as any tumordevelopment other than the aforementioned residual tumor.Results: A total of 103 patients (mean±SD age: 68.5±9.1 years; 93 men and 10 women) wereevaluated.
💡
Conclusion & Impact:Thepresence of carcinoma in situ (CIS) [Hazard ratio (HR): 3.00, 95% CI: 1.2-7.6, p=0.03], femalegender (HR: 2.38, 95% CI: 1.03-5.4, p=0.03) and age >70 years (HR: 1.87, 95% CI: 1.02-3.41,p=0.03) were significantly associated with recurrence.Conclusions: The present study showed that the presence of CIS, female gender, and age >70years were independently associated with the recurrence of NMIBC.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Özet

Aims: We aimed to assess patients with non-muscle invasive bladder cancer (NMIBC) to findout the factors affecting recurrence after initial treatment.Methods: In this retrospective cohort study, we investigated patients who underwenttransurethral bladder tumor resection (TURB) between January 2014 and April 2020. Patients’age, gender, initial symptoms, time from the initial symptoms to hospital admission, historyof systemic diseases, smoking history, pathological features, intra-vesical treatment recordsand information about recurrence were recorded. Recurrence was considered as any tumordevelopment other than the aforementioned residual tumor.Results: A total of 103 patients (mean±SD age: 68.5±9.1 years; 93 men and 10 women) wereevaluated. The mean diameter of the tumors was 3±1.6 cm. Following the initial TURB and/or re-TURB, 28 (27.1%) patients underwent induction chemotherapy or BCG therapy. Residualtumor was detected in 35 (34%) patients who were either detected within the first three monthsfollowing the TURB, without receiving any intravesical therapy, or in re-TURB performed forthe purpose of resection of the residual visible bulky lesions following an incomplete initialresection. Eleven patients (10.6%) recurred within a median of 18 months of follow-up. Themedian recurrence-free survival was 25 months (95% confidence interval (CI): 16.5-33.4). Thepresence of carcinoma in situ (CIS) [Hazard ratio (HR): 3.00, 95% CI: 1.2-7.6, p=0.03], femalegender (HR: 2.38, 95% CI: 1.03-5.4, p=0.03) and age >70 years (HR: 1.87, 95% CI: 1.02-3.41,p=0.03) were significantly associated with recurrence.Conclusions: The present study showed that the presence of CIS, female gender, and age >70years were independently associated with the recurrence of NMIBC.

🔖

Cite This Article

OKÇELİK, S., KIZILOZ, H., TEMEL, M. C., ACAR, R. (2021). Factors predicting recurrence in non-muscle invasive bladder cancers. Gülhane Tıp Dergisi, Cilt: 63 - Sayı: 3, 175–180. https://ajindex.com/articles/347978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953
  2. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234-241
  3. Gharibvand MM, Kazemi M, Motamedfar A, Sametzadeh M, Sahraeizadeh A. The role of ultrasound in diagnosis and evaluation of bladder tumors. J Family Med Prim Care. 2017;6:840-843
  4. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94:1-24
  5. Sun M, Trinh QD. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2015;29:205-218
  6. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447-461
  7. Chou R, Selph S, Buckley DI, et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol. 2017;197:1189-1199
  8. Baltacı S, Bozlu M, Yıldırım A, et al. Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy. Journal of Urological Surgery. 2016;3:74-79
  9. Luján S, Santamaría C, Pontones JL, et al. Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models. Actas Urol Esp. 2014;38:647-654
  10. Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. World J Urol. 2019;37:1867-1877
  11. Merseburger AS, Matuschek I, Kuczyk MA. Bladder preserving strategies for muscle-invasive bladder cancer. Curr Opin Urol. 2008;18:513-518
  12. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5;discussion: 475-477. 13. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430-442
  13. Palou J, Sylvester RJ, Faba OR, et al. Female g